Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia

American Journal of Cardiology

Volumn 79, Issue 11, 1997, Pages 1475-1481

  Davidson, Michael ^a,b,c,d,e   McKenney, James ^a,b,c,d,e   Stein, Evan ^a,b,c,d,e   Schrott, Helmut ^a,b,c,d,e   Bakker Arkena, Rebecca ^a,b,c,d,e   Fayyad, Rana ^a,b,c,d,e   Black, Donald ^a,b,c,d,e  

^a RADIANT RESEARCH   (United States)

^b National Clinical Research Inc   (United States)

^c Metabolic and Atherosclerosis Research Center   (United States)

^d Lipid Research Clinic   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ABDOMINAL PAIN; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 0030967489     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00174-4     Document Type: Article

References (22)

1. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE, Black DM. Reduction of LDL-cholesterol by 25-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
2. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
3. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control - National Heart, Lung, and Blood Institute Lipid Standardization program: an approach to accurate and precise lipid measurements. Clin Lab Med. 9:1989;105-135.
4. Remmell PS, Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), I: use of a dietary monitoring tool. JAMA. 76:1980;351-356.
5. Feskanich D, Buzzard IM, Welch BT, Asp EH, Dieleman LS, Chong KR, Bartsch GE. Comparison of a computerized and manual method of food coding for nutrient intake studies. J Am Diet Assoc. 88:1988;1263-1266.
6. Grundy SM, Vega SL. Role of apolipoprotein levels in clinical practice. Arch Intern Med. 150:((8)):1990;1579-1592.
7. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics' methodology (abstr). J Clin Chem Clin Biochem. 19:1981;850.
8. Steele WB, Koehle DF, Azar MM, Blaszkowski TP, Kuba K, Dempsey ME. Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique. Clin Chem. 22:1976;98-101.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of a centrifuge. Clin Chem. 18:1972;449-502.
10. Lipid and lipoprotein analysis. In: Manual of laboratory operations: LRC program report (NIH) 75-628. US Department of Health, Education, and Welfare, 1974, vol 1.
11. Marcovina SM, Adlophson JL, Parlavecchia M, Albers JJ. Effects of lyophilization of serum on the measurement of apolipoproteins A-I and B. Clin Chem. 36:1990;366-369.
12. Marcovina SM, Albers JJ, Henderson LO, Hannon HW. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. III: comparability of apolipoprotien A-I values by use of international reference material. Clin Chem. 39:1993;773-781.
13. Stein E, Kumbla L, Miller J, Srivastiva L, Kashyap M. Development and evaluation of a competitive ELISA for Lp(a) (abstr). Clin Chem. 38:1992;1067.
14. Ikenoya S, Takada M, Yuzurika K, Abe K, Katayama K. Studies on reduced and oxidized ubiquinones. I. Simultaneous determination of reduced and oxidized ubiquinones in tissues and mitochondria by high performance liquid chromatography. Chem Pharm Bull. 29:1981;158-164.
15. Lang JK, Gohil K, Packer L. Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Anal Biochem. 157:1986;106-116.
16. Laaksonen R, Jokelainen K, Tikkanen MJ, Himberg J-J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 57:1995;62-66.
17. Laaksonen R, Ojala J-P, Tikkanen MJ, Himberg J-J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 46:1994;313-317.
18. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 33:1993;226-229.
19. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis. 113:1995;157-166.
20. Bakker-Arkema R, Davidson M, Goldstein R, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-Co A reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
21. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 151:1991;43-49.
22. Laties AM, Shear CL, Lippa EA, Gould AL, Taylor HR, Hurley DP, Stephenson WP, Keates EU, Tupy-Visich MA, Chremos AN. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol. 76:1991;447-453.